Pharmacogenomics: from bedside to clinical practice
Open Access
- 15 April 2006
- journal article
- review article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 15 (90001) , R89-R93
Abstract
The field of pharmacogenomics has seen some exciting advances in the recent past. The Human Genome Project and International HapMap projects have uncovered a wealth of information for researchers. The discovery of clinically predictive genotypes (e.g. UGT1A1*28, TYMS TSER), haplotypes (e.g. VKORC1 Haplotype A) and somatic mutations (e.g. epidermal growth factor receptor), along with the introduction of FDA approved pharmacogenetic tests (UGT1A1*28) and the initiation of a genotype-guided clinical trial for cancer therapy (TYMS TSER in rectal cancer) have provided the first steps towards the integration of pharmacogenomics into clinical practice. This review describes some of the recent advances in pharmacogenomics research.Keywords
This publication has 38 references indexed in Scilit:
- Mutations of the epidermal growth factor receptor in non-small cell lung cancer – Search and destroyEuropean Journal of Cancer, 2006
- Thymidylate synthase pharmacogeneticsInvestigational New Drugs, 2005
- Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypesNature Genetics, 2005
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseNew England Journal of Medicine, 2005
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainPLOS Medicine, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- SNP databases and pharmacogenetics: great start, but a long way to goHuman Mutation, 2002
- A map of human genome sequence variation containing 1.42 million single nucleotide polymorphismsNature, 2001